AL8326 not checked
Advenchen Laboratories Nanjing Ltd.
FollowEvery change as it happens, and a Monday email
Trials
5 active
9 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “AL8326 is a novel small molecule multi-receptor tyrosine kinase inhibitor, which shows highly selective inhibition of fibroblast growth factor receptor (FGFr1, FGFr2, FGFr3), vascular endothelial growth factor receptor (VEGFr1, VEGFr2, VEGFr3) and Aurora-B.”In the company’s words, NCT07811232 on ClinicalTrials.gov
- Tested for
- Small Cell Lung Carcinoma, Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Non-Small Cell Lung, Solid Tumor, Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms and 1 more
- Main trialPhase 3
- “This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.”In the company’s words, NCT06247605 on ClinicalTrials.gov
Other drugs for Small Cell Lung Carcinoma
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up5
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- 7 Nov 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 1 Sep 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jul 2028 | A Phase IIII Study of AL8326 in Small Cell Lung Cancer | |
| Phase 2Recruiting | Dec 2027 | Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment | |
| Phase 1/2Recruiting | 7 Nov 2029 | A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. | |
| Phase 1/2Not yet recruiting | 1 Sep 2030 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | |
| Phase 1Active, not recruiting | Dec 2027 | A Study of AL8326 in Non-Small Cell Lung Cancer | |
| Phase 1/2Unknown | Sep 2021 | A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer | |
| Phase 1Unknown | Dec 2022 | A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects | |
| Phase 1Unknown | Dec 2023 | A Phase I Study of AL8326 in Advanced Solid Tumor | |
| Phase 1Completed | 17 May 2025 | A Study of AL8326 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026